anti apoe antibody mab41445  (R&D Systems)

Journal: Viruses

Article Title: HBV Pre-S1-Derived Myristoylated Peptide (Myr47): Identification of the Inhibitory Activity on the Cellular Uptake of Lipid Nanoparticles

doi: 10.3390/v13050929

Figure Lengend Snippet: Effect of Myr47 and its mutants on the ApoE3-LP interaction. ( A ) Effect of ApoE3 on the cellular LP uptake activity in the presence of Myr47 or its mutants. Hep G2 cells were incubated with DiD-LPs (5 μg/mL) in serum-free DMEM containing Myr47 or its mutants (500 nM) with/without ApoE3 (25 μg/mL) for 3 h at 37 °C, and then analyzed with flow cytometry. Data are shown as geometric means ± S.D. ( n = 3). ( B ) Effect of Myr47 or its mutants on the interaction of LPs and ApoE3 was evaluated with BLItz. Data are shown as means. ( n = 3).

Article Snippet: Anti-Human ApoE3 IgG (1 μM) was contacted with a protein A sensor chip (Fortebio) for 240 s. The sensor chip was washed with K-buffer (PBS containing 0.1% BSA) for 30 s. ApoE3 (2.5 μM) could bind with the antibody on the sensor chip for 120 s. The sensor chip was washed with K-buffer for 120 s. Meanwhile, mixture of LPs (500 μg/mL) and Myr47 or its mutants (50 μg/mL) was incubated at RT for 20 min and put in 4-μL well.

Techniques: Activity Assay, Incubation, Flow Cytometry

Journal:

Article Title: Sustained Phenotypic Correction in a Mouse Model of Hypoalphalipoproteinemia with a Helper-Dependent Adenovirus Vector

doi: 10.1038/sj.gt.3302819

Figure Lengend Snippet: Structures of adenoviral vectors used for co-injection

Article Snippet: For APOE3 immunoblot, goat anti-APOE antibody (1:4000, Calbiochem) or mouse monoclonal anti-human APOE3 (1:1000, SIGNET Lab) were used.

Techniques: Control

Journal:

Article Title: Sustained Phenotypic Correction in a Mouse Model of Hypoalphalipoproteinemia with a Helper-Dependent Adenovirus Vector

doi: 10.1038/sj.gt.3302819

Figure Lengend Snippet: Co-injection of FGAd vectors suppresses hAPOA1 expression mediated by HDAd-AI vector. (a) Plasma human APOA1 levels in APOA1−/− mice treated with Ad vectors. *p<0.05 vs. PBS, **p<0.01. (b) Plasma cholesterol levels in APOA1−/− mice after intravenous injection of Ad vectors. *p<0.05 vs. PBS, **p<0.01. (c) Immunoblot analysis of transgene expression. 0.1 μl of plasma collected from mice 8 weeks after treatment with various Ad vectors was separated by SDS-PAGE, and the presence of transgene products was detected by immunoblot. Upper panel: goat anti-human APOA1 antibody which does not cross react with mouse APOA1; middle panel: goat anti-apoE antibody; lower panel: mouse monoclonal antibody against human APOE3. Lane 1: Human plasma; lane 2: APOE−/− mouse; lane 3: APOE−/− mouse treated with HDAd-E3; lane 4: APOA1−/− mouse treated with FGAd-AI + HDAd-0; lane 5: APOE−/− mouse treated with HDAd-mouse APOE; lane 6: APOA1−/− mouse treated with HDAd-AI + HDAd-0; lane 7: APOA1−/− mouse treated with HDAd-AI and HDAd-E3; lane 8: APOA1−/− mouse treated with HDAd-AI + FGAd-E3. (d) Generation of anti-hAPOA1 antibodies after intravenous co-injection of various Ad vectors. *p<0.05 (vs. day 0).

Article Snippet: For APOE3 immunoblot, goat anti-APOE antibody (1:4000, Calbiochem) or mouse monoclonal anti-human APOE3 (1:1000, SIGNET Lab) were used.

Techniques: Injection, Expressing, Plasmid Preparation, Clinical Proteomics, Western Blot, SDS Page